Comments on “Short-term reasons for withdrawal and adverse events associated with apremilast therapy for psoriasis in real-world practice compared with in clinical …
EG Favalli, F Conti, F Atzeni, C Selmi… - Journal of the American …, 2018 - jaad.org
Baseline characteristics Female, n (%) 83 (63.3) 92 (54.8) 95 (58.6) 88 (53) 275 (55.3). 11
Mean age, y (SD) 57.5 (12) 51.4 (11.7) 50.5 (11.2) 49.9 (11.4) 50.6 (11.4) Mean duration of …
Mean age, y (SD) 57.5 (12) 51.4 (11.7) 50.5 (11.2) 49.9 (11.4) 50.6 (11.4) Mean duration of …
Repy to:“Comment on 'Drug survival of apremilast for psoriasis in a real-world setting'”
REFERENCES 1. Lee EB, Amin M, Wu JJ. Drug survival of apremilast for psoriasis in a real-
world setting. J Am Acad Dermatol. 2018. https://doi. org/10.1016/. jaad. 2018.03. 028. 2 …
world setting. J Am Acad Dermatol. 2018. https://doi. org/10.1016/. jaad. 2018.03. 028. 2 …
Long‐term 52‐week trends in apremilast safety outcomes for treatment of psoriasis in clinical practice: a multicentre, retrospective case series
A Ighani, JR Georgakopoulos, NH Shear… - British Journal of …, 2019 - academic.oup.com
DEAR EDITOR, Apremilast has demonstrated a favourable safety profile for the treatment of
psoriasis based on its pivotal randomized controlled trials (RCTs), ESTEEM 1 and 2. 1, 2 …
psoriasis based on its pivotal randomized controlled trials (RCTs), ESTEEM 1 and 2. 1, 2 …
[HTML][HTML] Apremilast survival and reasons for discontinuation in psoriasis: five-year experience from a Greek tertiary care centre
E Sotiriou, A Tsentemeidou, N Sideris… - Dermatology Practical …, 2022 - ncbi.nlm.nih.gov
Objectives To investigate the survival of apremilast in a cohort of psoriasis patients treated
with apremilast in a Greek hospital. Methods A retrospective cross-sectional study examined …
with apremilast in a Greek hospital. Methods A retrospective cross-sectional study examined …
Efficacy and Safety of Apremilast in Systemic-and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.
J Bagel, M Lebwohl, JM Jackson, R Chen… - Journal of drugs in …, 2018 - europepmc.org
BACKGROUND: Many patients with moderate plaque psoriasis are undertreated despite
broadening treatment options. In the phase IV UNVEIL study, oral apremilast demonstrated …
broadening treatment options. In the phase IV UNVEIL study, oral apremilast demonstrated …
Comparison of psoriasis guidelines for use of apremilast in the United States and Europe: a critical appraisal and comprehensive review
RI Ghamrawi, N Ghiam, JJ Wu - Journal of Dermatological …, 2022 - Taylor & Francis
Purpose This review article serves to compare global dermatologic organizations and the
available clinical practice guidelines for the use of apremilast in the treatment of psoriasis …
available clinical practice guidelines for the use of apremilast in the treatment of psoriasis …
Efficacy and safety of apremilast in patients with moderate plaque psoriasis with lower BSA: week 16 results from the UNVEIL study
B Strober, J Bagel, M Lebwohl… - Journal of drugs in …, 2017 - pubmed.ncbi.nlm.nih.gov
INTRODUCTION: Many options are available for patients with moderate to severe plaque
psoriasis. Patients with moderate disease, however, are often undertreated and do not …
psoriasis. Patients with moderate disease, however, are often undertreated and do not …
Real‐world, single‐centre experience of apremilast for the treatment of moderate to severe psoriasis
TH Wong, S Sinclair, B Smith, C Fraser… - Clinical and …, 2017 - academic.oup.com
The introduction of several new therapeutic agents, predominantly biologic therapies, has
transformed the management of moderate and severe psoriasis in recent years. A novel oral …
transformed the management of moderate and severe psoriasis in recent years. A novel oral …
40482 Early treatment intervention in moderate psoriasis keeps a long-term remission among patients with apremilast: a single-center observational study with 5 years …
E Tampouratzi, N Antonakopoulos, P Rigatos… - Journal of the American …, 2023 - jaad.org
Background: Introduction: Early treatment of psoriasis may modify the natural disease
course by maintaining long periods of remission reducing severity and preventing the …
course by maintaining long periods of remission reducing severity and preventing the …
Short-term reasons for withdrawal and adverse events associated with apremilast therapy for psoriasis in real-world practice compared with in clinical trials: A …
A Ighani, JR Georgakopoulos, NH Shear… - Journal of the American …, 2018 - jaad.org
P values were computed using the Pearson chi-square test, comparing the proportions
reported in the pooled RCTs with those in our cohort (boldface indicates statistically …
reported in the pooled RCTs with those in our cohort (boldface indicates statistically …